{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:50:12Z","timestamp":1790704212328,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010653","name":"Masaryk University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Teclistamab, a BCMA\u00d7CD3 bispecific antibody, demonstrates high efficacy in relapsed\/refractory multiple myeloma (RRMM). However, optimal dosing strategies outside clinical trials remain undefined. Thus, we performed a retrospective, multicentre analysis of 73 RRMM patients treated with teclistamab monotherapy at Czech Myeloma Group centres between 2023 and 2025. The study compared efficacy and safety between patients receiving standard weekly dosing and those with reduced-frequency dosing. The whole cohort had a median age of 67 years; 68.5% were penta-refractory. Dosing was de-escalated in 24.7% of patients, typically within one month of treatment initiation. Median progression-free survival (PFS) was 9.41 months and was comparable between weekly and non-weekly groups (9.1 vs. 11.3 months;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.141), despite a significantly lower relative dose intensity in the latter (60.5% vs. 87.0%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Infection rates and severe adverse events were similar between groups. A lower incidence of neutropenia was observed with less frequent dosing, but this did not translate into reduced infection burden. In conclusion, in real-world practice, early de-escalation of teclistamab dosing appears to maintain clinical efficacy. These findings support ongoing efforts to individualize treatment schedules with the aim of balancing effectiveness, tolerability, and patient-specific factors in BCMA-targeted therapy.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06529-1","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:58:39Z","timestamp":1755503919000},"page":"4141-4147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["De-escalated Teclistamab dosing in relapsed\/refractory multiple myeloma: Czech myeloma group real-world evidence analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Martin","family":"Stork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Radocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Mihalyova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Pika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Jungova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanna","family":"Boichuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Mensikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Sedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Krhovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Novakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Hornakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Knechtova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nela","family":"Sendlerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Dekojova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Maisnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"6","key":"6529_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"issue":"1","key":"6529_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V et al (2024) Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J 14(1):35. https:\/\/doi.org\/10.1038\/s41408-024-01003-z","journal-title":"Blood Cancer J"},{"issue":"2","key":"6529_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A et al (2024) Real-world analysis of Teclistamab in 123 RRMM patients from Germany. Leukemia 38(2):365\u2013371. https:\/\/doi.org\/10.1038\/s41375-024-02154-5","journal-title":"Leukemia"},{"key":"6529_CR4","doi-asserted-by":"crossref","unstructured":"Tan CRC, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E et al (2025) Real-world evaluation of Teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an international myeloma working group study. Blood Cancer J 15(1):53","DOI":"10.1038\/s41408-025-01259-z"},{"issue":"6","key":"6529_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A et al (2024) Incidence, timing, and management of infections in patients receiving Teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer 130(6):886\u2013900. https:\/\/doi.org\/10.1002\/cncr.35107","journal-title":"Cancer"},{"key":"6529_CR6","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1200\/JCO.2024.42.16_suppl.7536","volume":"42","author":"CRC Tan","year":"2024","unstructured":"Tan CRC, Derkach A, Maclachlan K, Hultcrant M, Hassoun V, Mailankody S et al (2024) Real-world schedule de-escalation of Teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol 42:7536\u20137536. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7536","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6529_CR7","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/blood-2024-208192","volume":"144","author":"HM Prince","year":"2024","unstructured":"Prince HM, Bahlis NJ, Rodr\u00edguez-Otero P, Karlin L, Akard Luke, Varshavsky-Yanovsky A et al (2024) MagnetisMM-3: Long-Term update of efficacy and safety of less frequent dosing of Elranatamab in patients with relapsed or refractory multiple myeloma. Blood 144(Supplement 1):4738. https:\/\/doi.org\/10.1182\/blood-2024-208192","journal-title":"Blood"},{"key":"6529_CR8","unstructured":"ClinicalTrials.gov MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM. NCT06171685. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06171685 [Accessed 27 Jun 2025]"},{"key":"6529_CR9","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","volume":"42","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Beksac M, Terpos E, Usmani SZ, Krishnan AY, Nijhof IS et al (2024) Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM). J Clin Oncol 42:7506","journal-title":"J Clin Oncol"},{"key":"6529_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1182\/blood-2024-206003","volume":"144","author":"MS Raab","year":"2024","unstructured":"Raab MS, Weinhold N, Kort\u00fcm KM, Kr\u00f6nke J, Podola L, Bertsch U et al (2024) Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Blood 144:493","journal-title":"Blood"},{"issue":"6","key":"6529_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R et al (2024) Correlation of immune fitness with response to Teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood 144(6):615\u2013628. https:\/\/doi.org\/10.1182\/blood.2023022823","journal-title":"Blood"},{"issue":"6","key":"6529_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A et al (2023) IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov 4(6):440\u2013451. https:\/\/doi.org\/10.1158\/2643-3230.BCD-23-0049","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"6529_CR13","doi-asserted-by":"publisher","first-page":"2039432","DOI":"10.1080\/2162402X.2022.2039432","volume":"11","author":"G Leclercq","year":"2022","unstructured":"Leclercq G, Servera LA, Danilin S, Challier J, Steinhoff N, Bossen C et al (2022) Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology 11(1):2039432. https:\/\/doi.org\/10.1080\/2162402X.2022.2039432","journal-title":"Oncoimmunology"},{"issue":"24","key":"6529_CR14","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"6529_CR15","doi-asserted-by":"publisher","unstructured":"Richter J, Thomas SK, Krishnan AY, Laubach JP, Cohen AD, Trudel S et al (2024) Cevostamab in Patients with Heavily Pretreated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies. Blood; 144 (Supplement 1): 1021. https:\/\/doi.org\/10.1182\/blood-2024-199542","DOI":"10.1182\/blood-2024-199542"},{"issue":"1","key":"6529_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","volume":"14","author":"M Merz","year":"2024","unstructured":"Merz M, Dima D, Hashmi H, Ahmed N, St\u00f6lzel F, Holderried TAW et al (2024) Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J 14(1):214. https:\/\/doi.org\/10.1038\/s41408-024-01197-2","journal-title":"Blood Cancer J"},{"issue":"9","key":"6529_CR17","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ, Chari A, Mateos MV (2024) Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol 11(9):e693\u2013e707. https:\/\/doi.org\/10.1016\/S2352-3026(24)00186-8","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06529-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06529-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06529-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:49:02Z","timestamp":1757663342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06529-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6529"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06529-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6764594\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS: Jonhson & Jonhnson: Consultancy, Other: Travel support, Honoraria for lectures JR: BMS: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Johnson & Johnson: Consultancy, Honoraria; GSK: Consultancy; Pfizer: Consultancy, Honoraria. TJ: Janssen: Consultancy, Other: Honoraria for lectures, Research Funding; Sanofi: Other: Honoraria for lectures, Research Funding; Pfizer: Consultancy,Other: Honoraria for lectures; BristolMyers Squibb:Other:Honoraria for lectures; GlaxoSmithKline: Consultancy, Other: Honoraria for lectures; Amgen: Research Funding. IS: BMS: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Travel Support; Amgen: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Travel support; Takeda: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Travel Support; GSK: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees. JM: Amgen: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; GSK: Membership on an entity\u2019s Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees. RH: Takeda: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy; BMS: Consultancy, Honoraria, Research Funding; PharmaMar: Consultancy, Honoraria; Novartis: Consultancy, Research Funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}